- 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD)
-
7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD).
- -
-
Paragraph 00141-00142; 00210
(2021/10/11)
-
- Preparation method of quinoline compound
-
The present invention relates to a preparation method of a quinoline compound, the quinoline compound has a structure represented by a formula (I), and the preparation method comprises the following steps: providing a compound having a structure represented by a formula (I-1); and reacting the compound with the structure shown in the formula (I-1) with 3, 4-difluoro-nitrobenzene to prepare the quinoline compound with the structure shown in the formula (I). The preparation method of the quinoline compound is high in production safety, low in cost and suitable for large-scale industrial production.
- -
-
Paragraph 0068-0073
(2020/03/09)
-
- BMP INHIBITORS AND METHODS OF USE THEREOF
-
The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
- -
-
Page/Page column 91
(2014/10/15)
-
- SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE
-
The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
- -
-
Page/Page column 20
(2012/09/10)
-
- COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
-
The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.
- -
-
Page/Page column 83
(2010/11/24)
-